We are only able to display limited information for this firm. We display more complete information for all of the following firms:
Katten is a popular choice among financial institutions, asset managers, public companies and their executives, in the defense of a wide range of securities class actions, stockholder derivatives cases, M&A litigation, proxy disclosure suits and SEC investigations and enforcement actions. The life sciences sector remains a fertile source of work, with New York-based Bruce Vanyo regularly defending high-profile sector specific issuers, including with regard to cases brought following alleged misstatements (including with regard to clinical trials) and subsequent stock price drops. Chicago-based Michael Diver co-chairs the team alongside Vanyo and leverages his previous experience at the SEC to good effect to clients facing enforcement actions from the regulator, including with regard to financial fraud, market manipulation and insider trading. The arrival in March 2024 of New York-based Kevin Broughel from Paul Hastings LLP strengthens the team in light of his deep understanding of the financial markets, products and regulations, and for matters involving cross-border issues.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'Bruce Vanyo is a really good negotiator, and an actual human being as well.'
- 'The Katten team, led by Mike Lohnes, was very accessible and experienced and employed great judgment.'
Key clients
- Astra Space, Inc.
- BioNTech, SE
Work highlights
- Defended PDVSA and PDVSA Petróleo (collectively, “PDVSA”) in a Section10(b) securities fraud lawsuit brought in the Southern District of New York in 2023 by an asset manager accusing PDVSA of fraud in connection with its issuance of nearly $2bn of senior secured notes in 2016.
- Represents clinical genetic testing company Natera and certain current and former officers and directors in a securities class action lawsuit pending in the US District Court for the Western District of Texas. The lawsuit asserts claims under the Exchange Act (1934), SEC Rule10b-5 and the Securities Act (1933) based on allegedly misleading statements made by Natera in its public disclosures concerning the accuracy of Natera’s testing technology and the company’s growth projections.